Medical purpose of NMDA acceptor antagonist and pharmaceutical composition thereof

Abstract

The invention discloses a medical purpose of an NMDA acceptor antagonist and a pharmaceutical composition thereof. The invention concretely discloses a medicine for using the NMDA acceptor antagonist, a pharmaceutically acceptable salt or a pharmaceutical composition thereof for treating or preventing central nervous system disease and / or mental diseases, and the NMDA acceptor antagonist is delivered to a human central nervous system through target administration. An application of the pharmaceutical composition can increase the concentration of the NMDA acceptor antagonist in brain tissue, medicine amount is greatly reduced, and systematic side effect is reduced; biology availability in the brain is high, autonomous drug administration can be carried out by patients, no pain is generated, usage is convenient, and thus the pharmaceutical composition has good patient compliance, and has wide clinical medical science application.

Description

Technical field [0001] The invention belongs to the technical field of medicine, and specifically relates to the medical use of an NMDA receptor antagonist and a pharmaceutical composition containing the NMDA receptor antagonist. Background technique [0002] Depression is a kind of mental disorder, with significant and lasting depression as the main clinical feature, and it is the main type of affective disorder. Clinically, it can be seen that depression is not commensurate with the situation. Emotional depression can range from gloomy to grief, low self-esteem, depression, or even pessimism, suicide attempts or behavior; even stupor; some cases have obvious anxiety and motor agitation; In severe cases, psychotic symptoms such as hallucinations and delusions may occur. Each attack lasts for at least 2 weeks, the elderly or even several years. Most cases have a tendency to recur. Most of each attack can be relieved, and some may have residual symptoms or become chronic. [0003]...

AI Technical Summary

Problems solved by technology

[0011] It is worth noting that the above-mentioned administration methods all deliver the drug to the blood and then reach the central nervous system through the systemic circulation, so before reaching the brain, GLYX-13 will be mostly eliminated by the body and cannot reach the brain tissue

In addition, the intravenous injection method itself still has the problem of patient compliance, because patients cannot inject intravenously by themselves, and must go to a medical institution to complete the administration, which brings great inconvenience to patients

[0012] Therefore, it is very necessary to solve the problems of high drug elimination rate and poor drug compliance caused by current drug delivery methods through new drug delivery methods and preparations.

Images